Specific tumor antigen (as recognized by engineered chimeric antigen receptor)

The phrase "Specific tumor antigens via engineered Chimeric Antigen Receptor" does not refer to a single canonical molecule or receptor, but rather describes a class of targetable cell surface antigens found on cancer cells and recognized by engineered chimeric antigen receptors (CARs) in adoptive T cell therapies. CARs are synthetic fusion proteins that equip T cells with the ability to recognize and kill cells presenting a selected antigen on their surface, independent of the major histocompatibility complex (MHC)[1][3][7]. These antigens are most commonly proteins or protein epitopes highly expressed on malignant but not normal cells, and the specific therapeutic target varies with the type of CAR construct, such as CD19 for B cell malignancies or BCMA for multiple myeloma. The overarching therapeutic principle is the genetic engineering of T cells to express a CAR that binds the patient's tumor antigen, triggering T cell activation and cytotoxicity[1][3][7]. This heading is not itself a single, unique molecular entity but is a category encompassing many possible specific antigens. Thus, it is not appropriate as a canonical target name; a correct entry should specify the exact tumor antigen (e.g., "CD19", "B cell maturation antigen"), as the structure, function, biology, and safety issues depend on the particular antigen being targeted[1][3][7]. Use of this broad phrase as a target is therefore considered incorrect for structured drug target annotation (is_incorrect: true). Key context: - CAR T cell therapy is a rapidly advancing area of cancer treatment using genetically engineered T cells expressing synthetic receptors specific for tumor antigens[1][3][5]. - Each clinical CAR-T product targets a particular antigen; CD19, BCMA, and others are current FDA-approved targets[3][7]. - Safety risks and efficacy depend critically on the choice of antigen and how specifically it distinguishes cancer from healthy cells[7][8]. For structured records, always replace this entry with a specific, validated tumor antigen (e.g., "CD19", "Epidermal growth factor receptor variant III") chosen for engineering into a chimeric antigen receptor[1][3][7].

Other names

Tumor-associated antigen for CAR T cell therapyCAR-targeted tumor antigenCAR T cell antigen

Immune cell-mediated cytotoxicity via engineered T cells targeting specific antigens